Abstract: The present disclosure relates to a composition comprising Coleus forskohlii extract, chlorogenic acid, and Garcinia cambogia extract and formulations of the same, which are useful in inhibiting adipogenesis.
Claims:1. A composition for inhibiting adipogenesis, said composition comprising:
a. Coleus forskohlii extract;
b. chlorogenic acid; and
c. Garcinia cambogia extract;
wherein Coleus forskohlii extract to chlorogenic acid w/w ratio in said composition is in the range of 2:1-1:2, chlorogenic acid to Garcinia cambogia extract w/w ratio in said composition is in the range of 2:1-1:2, and Garcinia cambogia extract to Coleus forskohlii extract w/w ratio in said composition is in the range of 2:1-1:2.
2. The composition as claimed in claim 1, wherein said Coleus forskohlii extract has forskolin content = 20%, and said Garcinia cambogia extract has hydroxyl citric acid content = 50%.
3. A method of preparing a composition as claimed in any of the claims 1-2.
4. A formulation for inhibiting adipogenesis, said formulation comprising:
a. Coleus forskohlii extract;
b. chlorogenic acid;
c. Garcinia cambogia extract, and
d. at least one carrier, diluent, and excipient,
wherein, Coleus forskohlii extract to chlorogenic acid w/w ratio in said composition is in the range of 2:1-1:2, wherein chlorogenic acid to Garcinia cambogia extract w/w ratio in said composition is in the range of 2:1-1:2, wherein Garcinia cambogia extract to Coleus forskohlii extract w/w ratio in said composition is in the range of 2:1-1:2.
5. The formulation as claimed in claim 5, wherein said Coleus forskohlii extract has forskolin content = 20%, and said Garcinia cambogia extract has hydroxyl citric acid content = 50%.
6. A method of preparing a formulation as claimed in any of the claims 4-5.
7. A method for inhibiting adipogenesis, said method comprising the steps of:
a. obtaining a composition comprising:
i. Coleus forskohlii extract;
ii. chlorogenic acid; and
iii. Garcinia cambogia extract;
b. contacting said composition with site of adipogenesis,
wherein Coleus forskohlii extract to chlorogenic acid w/w ratio in said composition is in the range of 2:1-1:2, wherein chlorogenic acid to Garcinia cambogia extract w/w ratio in said composition is in the range of 2:1-1:2, wherein Garcinia cambogia extract to Coleus forskohlii extract w/w ratio in said composition is in the range of 2:1-1:2.
8. A method for inhibiting adipogenesis, said method comprising the steps of:
a. obtaining a formulation comprising:
i. Coleus forskohlii extract;
ii. chlorogenic acid;
iii. Garcinia cambogia extract; and
iv. at least one carrier, diluent and excipient.
b. contacting said formulation with site of adipogenesis,
wherein Coleus forskohlii extract to chlorogenic acid w/w ratio in said formulation is in the range of 2:1-1:2, wherein chlorogenic acid to Garcinia cambogia extract w/w ratio in said formulation is in the range of 2:1-1:2, wherein Garcinia cambogia extract to Coleus forskohlii extract w/w ratio in said formulation is in the range of 2:1-1:2.
9. The method as claimed in any of the claims 7-8, wherein said Coleus forskohlii extract has forskolin content = 20%, and said Garcinia cambogia extract has hydroxyl citric acid content = 50%.
, Description:As Attached
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 5682-CHE-2015-NBA INTIMATION TO APPLICANT COMPLY WITH REQUIREMENT-30-11-2023.pdf | 2023-11-30 |
| 1 | Sequence listing [21-10-2015(online)].pdf | 2015-10-21 |
| 2 | Form 5 [21-10-2015(online)].pdf | 2015-10-21 |
| 2 | 5682-CHE-2015-Written submissions and relevant documents [06-07-2023(online)].pdf | 2023-07-06 |
| 3 | Form 3 [21-10-2015(online)].pdf | 2015-10-21 |
| 3 | 5682-CHE-2015-FORM-26 [23-06-2023(online)].pdf | 2023-06-23 |
| 4 | Drawing [21-10-2015(online)].pdf | 2015-10-21 |
| 4 | 5682-CHE-2015-Correspondence to notify the Controller [19-06-2023(online)].pdf | 2023-06-19 |
| 5 | Description(Complete) [21-10-2015(online)].pdf | 2015-10-21 |
| 5 | 5682-CHE-2015-US(14)-HearingNotice-(HearingDate-23-06-2023).pdf | 2023-06-06 |
| 6 | 5682-CHE-2015-Power of Attorney-301115.pdf | 2016-03-22 |
| 6 | 5682-CHE-2015-FER_SER_REPLY [07-03-2022(online)].pdf | 2022-03-07 |
| 7 | 5682-CHE-2015-Form 1-301115.pdf | 2016-03-22 |
| 7 | 5682-CHE-2015-FER.pdf | 2021-10-17 |
| 8 | 5682-CHE-2015-FORM 18 [05-09-2019(online)].pdf | 2019-09-05 |
| 8 | 5682-CHE-2015-Correspondence-301115.pdf | 2016-03-22 |
| 9 | 5682-CHE-2015-FORM 18 [05-09-2019(online)].pdf | 2019-09-05 |
| 9 | 5682-CHE-2015-Correspondence-301115.pdf | 2016-03-22 |
| 10 | 5682-CHE-2015-FER.pdf | 2021-10-17 |
| 10 | 5682-CHE-2015-Form 1-301115.pdf | 2016-03-22 |
| 11 | 5682-CHE-2015-Power of Attorney-301115.pdf | 2016-03-22 |
| 11 | 5682-CHE-2015-FER_SER_REPLY [07-03-2022(online)].pdf | 2022-03-07 |
| 12 | Description(Complete) [21-10-2015(online)].pdf | 2015-10-21 |
| 12 | 5682-CHE-2015-US(14)-HearingNotice-(HearingDate-23-06-2023).pdf | 2023-06-06 |
| 13 | Drawing [21-10-2015(online)].pdf | 2015-10-21 |
| 13 | 5682-CHE-2015-Correspondence to notify the Controller [19-06-2023(online)].pdf | 2023-06-19 |
| 14 | Form 3 [21-10-2015(online)].pdf | 2015-10-21 |
| 14 | 5682-CHE-2015-FORM-26 [23-06-2023(online)].pdf | 2023-06-23 |
| 15 | Form 5 [21-10-2015(online)].pdf | 2015-10-21 |
| 15 | 5682-CHE-2015-Written submissions and relevant documents [06-07-2023(online)].pdf | 2023-07-06 |
| 16 | Sequence listing [21-10-2015(online)].pdf | 2015-10-21 |
| 16 | 5682-CHE-2015-NBA INTIMATION TO APPLICANT COMPLY WITH REQUIREMENT-30-11-2023.pdf | 2023-11-30 |
| 1 | SearchHistoryE_28-07-2021.pdf |
| 1 | TKDlsearchstrategyE_28-07-2021.pdf |
| 2 | SearchHistoryE_28-07-2021.pdf |
| 2 | TKDlsearchstrategyE_28-07-2021.pdf |